170 related articles for article (PubMed ID: 11899360)
21. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
[TBL] [Abstract][Full Text] [Related]
22. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
24. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
25. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
26. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Wright TL; Twelves CJ
Eur J Cancer; 2002 Oct; 38(15):1957-60. PubMed ID: 12376198
[No Abstract] [Full Text] [Related]
27. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Castaneda CA; Gómez HL
Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
O'Shaughnessy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175
[TBL] [Abstract][Full Text] [Related]
29. The role of taxanes in the treatment of breast cancer.
Capri G; Tarenzi E; Fulfaro F; Gianni L
Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
[TBL] [Abstract][Full Text] [Related]
30. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
32. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
33. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Kashiwaba M; Inaba T; Komatsu H; Ishida K; Kawagishi R; Matsui Y; Uesugi N; Sugai T; Wakabayashi G
Oncology; 2014; 86(4):206-11. PubMed ID: 24820348
[TBL] [Abstract][Full Text] [Related]
35. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine-docetaxel combination treatment.
Mandelblat J; Bashir T; Budman DR
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1169-78. PubMed ID: 17020452
[TBL] [Abstract][Full Text] [Related]
38. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
40. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
Lopez M
Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
